A randomized controlled trial comparing a digitally delivered gut-directed hypnotherapy (GDH) program (Nerva) to an active control found that GDH significantly improved IBS symptoms and quality of life. Among 240 participants, 81% of those using the GDH program experienced a ≥50-point decrease in IBS symptom severity compared to 63% in the control group (P = 0.002). GDH also led to a greater reduction in pain (71% vs. 35%, P < 0.001) and quality-of-life improvements (P < 0.001). These findings support digital GDH as an effective and accessible alternative to in-person behavioral interventions for IBS management.
Trending
- Pfizer’s $10B monthly GLP-1 bet generates competitive weight loss in phase 2b (Fierce Biotech)
- ‘AI-native’ outpatient surgery startup Oath Surgical inks Nvidia partnership (Fierce Biotech)
- NVIDIA, Oath Surgical, ASCs and the Future of Physical AI in Healthcare (LSI | LinkedIn)
- UMass Successfully Performs Its First Full-Thickness Resection Device Procedure (UMass Chan Medical School)
- 5 gastroenterology physician moves in 1 month (Becker’s GI & Endoscopy)
- Artificial Intelligence on Trial: Who’s Liable When Clinical Algorithms Go Wrong? (Medscape)
- Building the Future Gastroenterologist: Why Nutrition and Lifestyle Medicine Must Be Core Competencies (ACG Case Reports Journal)
- Spray Cryotherapy Esophageal Consortium Consensus Recommendations for Liquid Nitrogen Spray Cryotherapy in Barrett’s Esophagus and Esophageal Cancer Using a Modified Delphi Process (The American Journal of Gastroenterology)
